These compounds demonstrated efficacy in suppressing tumor growth in HPV-associated cancer models with concomitant increases in p53-dependent transactivation and decreases in E6-UBE3A complex formation, further validating E6-UBE3A as a viable therapeutic target in HPV-driven malignancies. This evidence concerns the gene TP53 and cancer.